Nuwellis, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 18, 2025, reports significant changes to the executive leadership and Board of Directors of Nuwellis, Inc. (Nasdaq: NUWE), a medical device company. The report details the retirement of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. However, it discloses specific compensation-related financial obligations:
- Outgoing CEO Bonus: A one-time lump sum payment of $47,723.42 for the 2024 bonus.
- Outgoing CEO Severance: Six months of base salary continuation.
- Outgoing CEO Benefits: Company-paid COBRA health premiums through August 31, 2025.
- Interim CEO Salary: Annual salary of $300,000 for the new Interim CEO.
Material Changes
The primary material change is the departure of Nestor Jaramillo, Jr., who retired as President, Chief Executive Officer, and Board member effective February 18, 2025. The Board size was reduced from seven to six members. The retirement was not the result of any dispute with the Company. Concurrently, John L. Erb was appointed as Interim President and Chief Executive Officer, effective February 18, 2025.
Guidance, Outlook, and Management Commentary
The filing does not contain updated financial guidance or operational outlook. Management commentary is limited to the announcement of the leadership transition. The Board appointed Mr. Erb, a former CEO of the Company (2015–2021) and long-time director, to ensure continuity. No unusual items or contingencies were disclosed beyond the standard separation agreement terms.
Key Facts for Investor Verification
- Verify the total cost of the separation package for Nestor Jaramillo, Jr., including the specific base salary amount for the six-month continuation period.
- Confirm the vesting acceleration details for Mr. Jaramillo's outstanding stock options.
- Review the full text of the Separation Agreement (Exhibit 10.1) and the Interim CEO Letter Agreement (Exhibit 10.2) for additional covenants or restrictions.
- Monitor future filings for the appointment of a permanent CEO and any strategic shifts under the interim leadership.